- Home
- MMA vs HSCS Comparison
MMA vs HSCS Comparison
Compare MMA & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | HSCS |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 15.8M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MMA | HSCS |
|---|---|---|
| Price | $0.37 | $3.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 280.0K | 136.1K |
| Earning Date | 10-30-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | N/A | $18,321.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $1.63 |
| 52 Week High | $1.72 | $5.25 |
Technical Indicators
Market Signals| Indicator | MMA | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 54.67 |
| Support Level | $0.36 | $1.84 |
| Resistance Level | $0.44 | $4.35 |
| Average True Range (ATR) | 0.03 | 0.46 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 54.66 | 45.00 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.